Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

BlueRock Therapeutics

Main focus: Cell therapies

Company stage: Clinical

Diseases: Neurology, cardiology, immunology and ophthalmology

Genome-editing tool: CRISPR

Funding stage: Private (acquired, subsidiary of Bayer AG)

Location: Cambridge, MA (headquarters)



Partners: Editas Medicine, Bayer AG

BlueRock Therapeutics is a leading engineered cell therapy company with a mission to create authentic cellular medicines to reverse devastating diseases, with the vision of improving the human condition. The Company’s cell+gene platform harnesses the power of cells to create new medicines for neurology, cardiology, immunology and ophthalmology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce authentic cells, some of which are engineered for additional therapeutic function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore lost function. BlueRock Therapeutics was founded in 2016 by Versant Ventures and Bayer AG and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG (through its Leaps by Bayer unit) and Versant Ventures. The company was fully acquired by Bayer in 2019. BlueRock Therapeutics’ culture is defined by the courage to persist regardless of the challenge, the urgency to transform medicine and deliver hope, integrity guided by mission, and community-mindedness with the understanding that we are all part of something bigger than ourselves.


HashtagBlueRock Therapeutics, LLC.

Company: BlueRock Therapeutics
Search CRISPR Medicine